Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.
about
Complex role of autophagy in regulation of hepatic lipid and lipoprotein metabolismNon-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?GLP-1 and cardioprotection: from bench to bedsideLiraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trialMouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease.Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure.Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits.Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1.Targeting metabolic disturbance in the diabetic heart.Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrixComparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats.Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids.Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance.Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.Cardiovascular biology of the incretin system.Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis.The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities.Extrapancreatic effects of incretin hormones: evidence for weight-independent changes in morphological aspects and oxidative status in insulin-sensitive organs of the obese nondiabetic Zucker rat (ZFR).The relationship between visceral adiposity and left ventricular diastolic function: results from the Baltimore Longitudinal Study of Aging.High fructose causes cardiac hypertrophy via mitochondrial signaling pathway.Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats.The role of gastrointestinal hormones in hepatic lipid metabolism.Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.Prophylactic effects of the glucagon-like Peptide-1 analog liraglutide on hyperglycemia in a rat model of type 2 diabetes mellitus associated with chronic pancreatitis and obesity.Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.Review article: new treatments in non-alcoholic fatty liver disease.Treatment options for nonalcoholic steatohepatitis - a safety evaluation.Novel Pharmacotherapy Options for NASH.Emerging and future therapies for nonalcoholic steatohepatitis in adults.Liraglutide reduces lipid accumulation in steatotic L‑02 cells by enhancing autophagy.C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis.Metabolomic profiling reveals differential effects of glucagon-like peptide-1 and insulin on nutrient partitioning in ovine liver.Panhypopituitarism due to Absence of the Pituitary Stalk: A Rare Aetiology of Liver CirrhosisThe cardiometabolic benefits of glycine: Is glycine an 'antidote' to dietary fructose?
P2860
Q26747101-6E5EEA6B-B830-44FA-A5F4-F945F9B4D747Q27006992-A4C58940-54BC-4127-BEC8-DC0AE3B5F47AQ27024984-F54216BC-A350-4BC4-BE34-6F8B4C43A6C9Q28661700-8CB28E49-15AA-4540-95CF-96BE5D129DC4Q30375036-B4A60F2D-487C-447C-B86F-0DD86AB3A7D6Q30577903-F0E6C272-76FC-4AB2-9666-FFC7D4341B9EQ31149434-D11F4ED5-64E1-4860-A9B0-FDDF5B014973Q33603384-C6B9B058-3B88-4D42-8EA3-F1901D3091CAQ33838133-57EF2E33-25C5-4344-AFB0-B6093EE18076Q34379379-93511C07-89E0-4483-8D65-BF9A6B545481Q35047406-6141E2B6-EDF9-472A-B6F9-5A5C17EC9244Q35084845-E4764B6D-1FBE-4C64-9985-44278D424CF1Q35132702-F90A69AB-7725-4A83-9E13-BFF1EC0BAAF4Q35276899-96BB04C7-327E-47A5-9849-C965C92065EDQ36237911-3A249896-605C-47EE-BD42-313BE80C2715Q36259181-978A6599-1334-4498-8750-EEF7CA4E8A4EQ36465496-7BD39608-B827-4F85-A3ED-5431FEBC01D8Q36484283-6CACB900-9F29-40D1-97E5-21A3D7A2FAA4Q36505119-2C40F900-845A-4E4E-9D51-F7F9A453D8B2Q37024780-450B03EA-1433-429D-AE01-5319D62D4615Q37176743-B1F833CD-0200-460A-A900-CB01C550289FQ37330250-4F0DB275-42EB-4ECF-BC43-654C3A42C8E6Q37448172-EB3124B7-2731-428F-A6A9-9F638628AEABQ37629687-13E9D4D7-24AD-4CE2-9309-0CCC9C044D65Q37640700-663F443B-346E-46D8-8F4C-29FA3E7F113CQ37671303-B3AD89E0-FBBD-4F97-9E58-11C459A4451AQ37719449-59E6B3B1-5707-47BC-B16C-4ED46198C5B6Q38121574-9530D963-6F81-4C80-BE18-5EDAB57D4A8CQ38234416-8F6DA6C7-9777-4789-A437-EAAFD657526EQ38527138-5741F1CD-9D4A-4121-A4E5-4B8D3A270A76Q38537853-1083C133-2944-4261-8B1D-1D839F14E6DDQ38662765-1728CF1A-6B99-469E-BE85-8CA9C78ADEEFQ38713765-3C7C3BF8-225B-465B-8D87-26C223783480Q38784790-AEE82C53-E859-475E-99E2-298BDF85F537Q38827586-B1EDEE3D-75AC-4E62-8A50-75DA4B030282Q38955646-44CE36AA-6333-455B-B402-F0F84E985615Q39726227-7A8A12F4-D568-4B8C-A726-290257D3A5BEQ39909178-23F892F4-C4DB-4409-B12E-D96CC30505ACQ41150264-B3C9B860-6471-4457-AB86-E4D945FC650AQ41816192-3768C749-984A-4C77-B3F9-14E1D334C482
P2860
Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Glp-1 analog, liraglutide, ame ...... BL/6J mice fed a Western diet.
@ast
Glp-1 analog, liraglutide, ame ...... BL/6J mice fed a Western diet.
@en
type
label
Glp-1 analog, liraglutide, ame ...... BL/6J mice fed a Western diet.
@ast
Glp-1 analog, liraglutide, ame ...... BL/6J mice fed a Western diet.
@en
prefLabel
Glp-1 analog, liraglutide, ame ...... BL/6J mice fed a Western diet.
@ast
Glp-1 analog, liraglutide, ame ...... BL/6J mice fed a Western diet.
@en
P2093
P2860
P356
P1476
Glp-1 analog, liraglutide, ame ...... BL/6J mice fed a Western diet.
@en
P2093
Dan Sorescu
Darin Olson
Frank A Anania
Jamie E Mells
Jeffrey A Handy
Lihong Cheng
Neeraj K Saxena
Shvetank Sharma
P2860
P304
P356
10.1152/AJPGI.00274.2011
P577
2011-10-28T00:00:00Z